Article By:
Insider Monkey
Wednesday, October 30, 2019 10:18 AM EDT
Judging by the fact that Reata Pharmaceuticals, Inc. has faced falling interest from the aggregate hedge fund industry, it’s easy to see that there lies a certain “tier” of fund managers that slashed their positions entirely heading into Q3.
In this article: RETA